taiwan
suffer
outbreak
sever
acut
respiratori
syndrom
sar
laboratori
perform
seri
virolog
serolog
test
sar
patient
admit
hospit
crossreact
found
test
antibodi
human
tcell
lymphotrop
viru
htlv
one
patient
sar
therefor
antibodi
htlv
examin
pairedsera
sar
patient
elisa
neutral
test
use
measur
antisar
antibodi
seroconvers
antibodi
sarscov
observ
patient
surprisingli
use
elisa
htlv
sera
patient
posit
htlv
seroconvers
htlv
also
observ
patient
western
blot
htlv
pairedsera
htlvposit
patient
display
posit
result
htlvi
posit
result
htlvii
posit
result
htlvi
ii
neg
result
either
htlvi
htlvii
indetermin
result
find
antibodi
htlv
detect
blood
sampl
collect
sar
patient
provid
import
inform
safe
handl
blood
product
without
knowledg
blood
product
discard
mistakenli
even
though
contain
antisarscov
antibodi
may
potenti
valuabl
sar
therapi
sever
acut
respiratori
syndrom
sar
new
infecti
diseas
caus
previous
unrecogn
coronaviru
ksiazek
et
al
poutanen
et
al
rota
et
al
peiri
et
al
sar
origin
southern
china
spread
mani
countri
region
includ
taiwan
chan
et
al
latter
experienc
sar
outbreak
march
june
suffer
probabl
case
sar
confirm
death
wu
et
al
hospit
patient
recov
sar
readi
discharg
day
onset
diseas
patient
donat
blood
research
use
biosafeti
reason
seri
routin
test
conduct
detect
antibodi
human
immunodefici
viru
hiv
human
hepat
b
c
viru
hbv
hcv
human
tcell
lymphotrop
viru
htlv
result
htlv
posit
htlv
elisa
kit
murex
htlv
abbott
laboratori
chicago
il
time
sera
collect
antibodi
sar
coronaviru
sarscov
also
detect
serum
patient
earlier
serum
collect
patient
day
diseas
onset
retest
found
result
neg
sarscov
htlv
antibodi
result
suggest
antisar
antibodi
might
recogn
htlv
antigen
therefor
examin
antibodi
respons
use
sera
addit
sar
patient
patient
diagnos
probabl
sar
infect
base
clinic
manifest
contact
histori
suggest
age
patient
rang
year
old
twentythre
femal
three
male
sera
collect
april
februari
neutral
test
antisarscov
assay
serum
test
twofold
serial
dilut
use
mem
moreov
ml
dilut
serum
mix
ml
sarscov
plate
hr
incub
ml
ml
cell
ad
well
plate
incub
day
result
read
cpe
appear
viru
control
well
least
five
well
control
use
per
experi
three
type
control
also
includ
neutral
test
name
cell
control
cell
mem
serum
control
serum
mem
cell
viru
control
mem
cell
elisa
antigen
use
antisarscov
antibodi
detect
detergentextract
gammairradi
vero
cell
infect
sarscov
similar
prepar
uninfect
vero
cell
use
control
patient
sera
dilut
ten
time
ad
elisa
plate
goat
antihuman
igg
antibodi
conjug
horseradish
peroxidas
dako
camridgeshir
uk
ad
enzymat
reaction
follow
addit
substrat
ophenylenediamin
optic
densiti
od
valu
measur
nm
wavelength
cut
valu
use
elisa
peiri
et
al
rota
et
al
chan
et
al
elisa
detect
antihtlv
antibodi
patient
elisa
commerci
kit
abbott
murex
htlv
use
antihtlv
antibodi
detect
base
microwel
coat
synthet
peptid
repres
immunodomin
region
htlvi
htlvii
envelop
protein
recombin
transmembran
protein
htlvii
rouet
et
al
cut
valu
use
elisa
commerci
western
blot
kit
htlv
blot
genelab
diagnost
singapor
use
base
nitrocellulos
strip
incorpor
htlvi
htlvii
viral
core
envelop
protein
rouet
et
al
interpret
result
accord
criteria
describ
kit
seroneg
repres
reactiv
htlv
specif
protein
htlvi
seroposit
reactiv
gag
without
env
htlvii
seroposit
reactiv
gag
env
htlv
seroposit
specif
reactiv
gag
without
env
observ
indetermin
indic
htlv
specif
band
detect
meet
criteria
htlvi
htlvii
htlv
seroposit
describ
serum
convers
antibodi
sarscov
observ
patient
use
sarsigg
elisa
sarsneutr
test
tabl
surprisingli
patient
seroposit
htlv
elisa
abbott
murex
assay
among
patient
patient
od
valu
htlv
elisa
second
sera
nine
patient
found
greater
one
seroconvers
htlv
also
observ
patient
except
patient
first
sera
found
strongli
posit
od
antibodi
htlv
second
sera
pairedsera
patient
test
western
blot
analysi
htlv
htlv
blot
genelab
diagnost
singapor
figur
second
sera
ten
sar
patient
show
htlv
seroconvers
well
first
sera
patient
reactiv
gag
protein
except
second
serum
patient
serum
coincident
lowest
od
valu
among
second
sera
ten
patient
seroconvers
htlv
elisa
tabl
reactiv
found
patient
second
sera
except
serum
first
sera
patient
accord
seroposit
definit
describ
manufactur
see
materi
method
western
blot
pairedsera
patient
display
five
posit
htlvi
serum
seven
posit
htlvii
serum
one
posit
htlvi
ii
serum
nine
neg
either
htlvi
ii
serum
four
indetermin
serum
notabl
htlv
western
blot
assay
intens
posit
band
appear
sar
patient
much
weaker
trueli
htlvinfect
patient
comparison
posit
control
fig
lane
specul
sarscov
peptid
common
htlv
might
respons
fals
posit
result
observ
htlv
antibodi
detect
retriev
analyz
sarscov
full
genom
well
htlv
full
genom
includ
htlvi
htlvii
genbank
may
annot
code
sequenc
crossexamin
search
common
peptid
longer
six
aminoacid
residu
sarscov
htlv
four
common
peptid
found
list
tabl
ii
among
rfpnitn
locat
spike
protein
sarscov
envelop
protein
env
htlvi
lallll
locat
nucleocapsid
protein
n
sarscov
envelop
protein
htlvii
four
common
peptid
synthes
test
crossreact
antibodi
sera
sar
versu
htlvinfect
patient
figur
show
puriti
synthes
peptid
conjug
ovalbumin
preliminari
analysi
one
htlvinfect
patient
recruit
addit
one
serum
second
serum
patient
serum
select
sar
patient
describ
earlier
test
sera
use
synthes
peptid
neg
sera
provid
htlv
kit
control
also
includ
shown
figur
serum
sar
patient
htlv
patient
react
common
peptid
western
blot
reactiv
found
control
serum
preval
rate
htlv
taiwan
approxim
lu
et
al
studi
show
cutoff
valu
htlv
calcul
accord
suggest
manufactur
htlv
seroposit
rate
sar
patient
suggest
antibodi
sarscov
might
crossreact
htlv
crossexamin
code
sequenc
pathogen
reveal
four
common
peptid
might
respons
fals
posit
result
describ
four
common
peptid
synthes
test
crossreact
antibodi
sera
sar
versu
htlv
infectedpati
result
show
sera
either
htlv
sar
patient
react
four
synthet
peptid
fig
sinc
one
serum
htlv
one
sarscov
infect
patient
test
result
obtain
studi
consid
preliminari
viral
spike
protein
nucleocapsid
protein
envelop
protein
mani
virus
consid
possess
antigen
serum
antibodi
figur
notic
certain
protein
respons
crossreact
observ
exampl
htlvi
htlvii
among
four
common
peptid
synthes
test
notic
lallll
rfpnitn
part
transmembran
glycoprotein
locat
next
product
env
accord
genbank
annot
moreov
aletpv
part
major
core
protein
locat
next
product
gag
although
known
whether
commerci
use
label
synonym
found
genbank
annot
appear
found
common
peptid
correl
display
band
respons
crossreact
report
crossreact
htlv
occurr
sampl
patient
infect
pathogen
plasmodium
falciparum
hay
et
al
resid
napsan
philippin
site
endem
plasmodium
falciparum
found
posit
htlv
elisa
western
blot
immunoreact
two
htlv
protein
present
elisa
posit
sera
elisa
posit
sera
react
howev
reactiv
env
protein
find
show
sar
patient
posit
htlv
elisa
western
blot
immunoreact
two
htlv
protein
present
htlvseroposit
patient
elisa
posit
reaction
elisa
posit
reactiv
contrast
studi
plasmodium
falciparum
elisa
posit
patient
reactiv
env
protein
note
earlier
collect
sampl
sinc
diseas
onset
tabl
serum
show
seroposit
od
valu
greater
antihtlv
test
yet
neg
antisar
test
among
antibodi
sera
sar
patient
antibodi
peptid
lallll
locat
n
protein
sarscov
might
develop
earlier
antibodi
inactiv
viru
differenti
sensit
test
use
studi
might
caus
result
howev
possibl
someth
specif
htlv
antisarscov
antibodi
develop
earlier
sar
patient
respons
crossreact
exclud
design
synthet
peptid
diagnost
reagent
bioinformat
approach
combin
inform
sequenc
databas
would
provid
use
tool
avoid
possibl
crossreact
among
pathogen
consequ
import
maintain
comprehens
sequenc
databas
infecti
microorgan
moreov
mani
reagent
use
current
reexamin
newli
emerg
virus
result
pairedsera
patient
label
figur
first
serum
second
serum
htlv
seroposit
reactiv
gag
without
env
htlvi
reactiv
htlvii
reactiv
w
weak
display
next
lane
present
reactiv
specif
band
larg
part
band
exhibit
w
patient
first
sera
lack
specif
band
except
serum
exhibit
one
extra
nonspecif
band
shown
sequenc
level
prevent
potenti
fals
posit
result
laboratori
diagnosi
accord
recommend
sar
patient
donat
blood
month
diseas
onset
trace
antisar
antihtlv
antibodi
five
sar
patient
prolong
period
time
antibodi
titer
sar
still
high
od
day
diseas
onset
antibodi
titer
htlv
mostli
declin
od
find
suggest
among
antibodi
sera
sar
patient
crossreact
htlv
peptid
might
disappear
six
sar
coronaviru
genom
urbani
seven
genom
eight
genom
earlier
notabl
one
five
patient
still
seroposit
htlv
day
data
shown
wait
effect
drug
vaccin
treatment
develop
sar
antibodi
found
patient
alreadi
recov
diseas
repres
valuabl
resourc
potenti
therapi
futur
sar
patient
without
note
antihtlv
reactiv
detect
sar
patient
could
due
crossreact
report
studi
valuabl
blood
product
unnecessarili
discard
